New immunotherapies represent one of the most significant breakthroughs in recent decades for people with cancer, validating the
The initial narrow focus on checkpoint inhibition fails to address the multitude of additional processes known to play a role in enabling cancer cells to escape immune detection and eradication, ultimately limiting these therapies’ impact and reach.